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Radiology is facing many challenges nowadays, and certainly needs to keep up with the fast pace of developments
taking place in this field. This editorial aims at drawing the attention of the reader to the current establishment of
quantitative imaging biomarkers, in particular through the efforts of the Quantitative Imaging Biomarker Alliance (QIBA)
from the Radiological Society of North America (RSNA), as well as the European Imaging Biomarker Alliance (EIBALL) from
the European Society of Radiology (ESR). The case of arterial spin labelling (ASL) is used as an example of the long and
winding road to translate a good imaging technique into a clinically relevant imaging biomarker.
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 Radiology is moving from pattern recognition by
experts to a specialty based on the measurements of
physical quantities
 In order to move from pattern recognition to the
scientific assessment of measurement techniques,
new paradigms need to be followed
 The two largest radiological associations in the
world are leading the way through the establishment
of dedicated committees working on this
transformation
 Arterial spin labelling (ASL), an MRI technique used
for the measurement of perfusion, is proposed as a
demonstration of what is needed to transform an
imaging technique into a quantitative imaging
biomarker
Introduction
Radiology is currently at a crossroads. Having been the
first medical specialty to endorse the digital revolution,
it is also the first to face the amazing opportunities, but
also the profound threats, from artificial intelligence
[1]. Such algorithms might one day be good enough to
provide substantial help to radiologists everywhereCorrespondence: x.golay@ucl.ac.uk
UCL Institute of Neurology, Queen Square 8-11, London WC1N 3BG, UK
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larly good in helping them peruse the hundreds of
sections typically provided by modern MRI or CT scan-
ners for their reporting. Some fear, however, that they
might be powerful enough to replace the radiologist
altogether.
In parallel, another revolution is taking place, at a less
mediatised rate but no less certainly than the AI one,
and it has to do with quantification. Quantification in
radiology starts with simple anatomical precision, and
the well-known Response Evaluation Criteria In Solid
Tumours criteria [2] used for assessment of treatment
response in cancer are based on the premise that meas-
urement of size can be made reproducibly over time,
even if the patient is not scanned by the same machine
functioning on the same software level. While these
criteria are rather rough and simple, the issue of repro-
ducibility and anatomical precision becomes already
more challenging when MRI (or less frequently CT) is
used to assess the slow reduction in grey matter taking
place in dementia over time [3]. Precision becomes
particularly crucial now that the new diagnostic criteria
for dementia are based on an increase in the yearly rate
of atrophy, at typically 2% for Alzheimer’s patients, with
respect to the general population (0.5% per annum from
the age of 40 years) [4, 5]. The issue only becomes more
difficult to handle when such criteria are used asis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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of patients need to be individually followed up, and for
which precision needs to be maintained throughout the
whole duration of the trial.
In this context, the pioneering natural history study
called Alzheimer’s Disease Neuroimaging Initiative has
established some of the necessary requirements needed
in terms of quality assurance and reproducibility, as well
as presence of artefacts [6]. Through its first results,
published several years ago, extensive collaboration be-
tween basic scientists, statisticians and clinicians has
allowed the development of the necessary standards for
the use of imaging as an outcome measure in large trials.
It thereby showed the necessity to use objects treated as
reference standards across the various sites to ensure
that no subtle drift was present, or that a scheduled soft-
ware upgrade on a machine did not change the results
dramatically [6].
Furthermore, the last 20–30 years have seen another
revolution, beyond simple anatomical imaging, through
which basic scientists and manufacturers have joined
forces with radiologists to increase both the quality and
the information content of the medical imaging equip-
ment available. Quantitative imaging has gained a new
meaning through the development of most physio-
logical imaging techniques, be it, e.g. perfusion CT [7],
Gd-based perfusion MRI [8], ASL [9] or diffusion-
weighted imaging [10] and its many applications, from
the assessment of white matter fibre tracts in the brain
[11] to the detection and assessment of early changes
in water diffusion in cancer [12]. Yet, following from
30 years of development leading these techniques to be
widely used in most oncological examinations everywhere
in the body, they are today still mostly interpreted in a
semiqualitative way by radiologists around the world. This
is happening in the face of a large body of evidence indi-
cating that the quantitative measures themselves obtained
by many of these techniques could serve as early indica-
tors of the presence of disease or indeed as biomarkers of
response to treatment [13–16]. In addition, these tech-
niques offer the added advantage of being usable as
translational biomarkers between late preclinical stud-
ies involving animal models and first-in-man studies,
thereby providing early indications of its potential
therapeutic power. As such, it is hoped that the use of
quantitative physiological imaging as translational bio-
markers by basic scientists and clinicians alike might one
day allow a shortening of the time to market of new thera-
peutics. More importantly for this community, it will nat-
urally increase the participation by radiology departments
in clinical trials, and ensure its more frequent position as
a leading partner.
So, as radiology, like many other medical specialties,
moves towards a more evidence-based approach, and asquantification becomes an ever more important part of its
practice, it becomes necessary for it to become more pre-
cise, and with precision comes the need to become more
scientific. In particular, the implementation of quantitative
anatomical and physiological imaging requires the use of
very strict rules based on metrology, the science dealing
with measurement. This is particularly difficult for radi-
ology, owing to the differences between the acquisition
and analysis tools available on the market, as well as the
independent activities of the clinicians. It is, therefore, ab-
solutely necessary for the field to move forward to increase
the collaboration between basic scientists and clinicians in
order to overcome the hurdles linked with the develop-
ment of quantitative imaging biomarkers. Understanding
the seriousness of these issues, the Radiological Society of
North America decided in 2007 to establish the Quantita-
tive Imaging Biomarker Alliance (QIBA) as a means to
unite researchers, health care professionals, and industry
stakeholders to advance the use of quantitative imaging in
general [17].
Through QIBA, scientists, clinicians and mathemati-
cians hope to validate quantitative imaging biomarkers,
based on metrological practices such as identification and
characterisation of the sources of error. In addition, a de-
tailed analysis of the entire imaging chain will need to be
undertaken, from acquisition to processing, to be able to
establish the presence or not of a bias along the entire
measurement procedure. Here again, estimation of a bias
size is generally made through the use of objects serving
as ‘gold standards’ or benchmarks for the measurements
done. These objects are generally called phantoms and
their role will, therefore, be more and more important
within the growing field of quantitative radiology.
In Europe as well, responding to the urgent need to
promote the development of imaging biomarkers, the
European Society of Radiology (ESR) has created a stand-
ing subcommittee from its Research Committee, called
the European Imaging Biomarker Alliance (EIBALL). This
committee aims at promoting the development of bio-
markers within the realm of the ESR, and has recently
joined forces with the European Institute of Biomedical
Imaging Research to start working on Europe based pro-
jects in this matter. In particular, the EIBALL Committee
has recently joined forces with QIBA to work on the first-
ever EIBALL-QIBA project on the development of a new
quantitative imaging biomarker, based on the ASL perfu-
sion measurement technique.
A typical case of biomarker development: ASL
The case of ASL is rather typical for a quantitative im-
aging technique. Started in the early 1990s [9], the
method underwent many technical improvements
through a decade of developments by MRI physicists
and engineers. This left the field in the early 2000s with
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manufacturers to pick and choose one each differently
as a work-in-progress package [18]. In addition, at that
time, no clear consensus existed in terms of quantifica-
tion, and every researcher and the few clinicians inter-
ested in the applications of this method were left with a
rather daunting choice for quantification models, each
providing a slightly different answer, depending on its
underlying hypotheses [19].
Therefore, the community had to do something to try
to sort out the two main issues plaguing the field: (1) the
plethora of acquisition techniques and (2) the lack of con-
sensus on the quantification method. In addition, nobody
even knew whether this technique was reproducible, apart
from a handful of volunteers being scanned repeatedly at
single institutions. Indeed, it took nearly 20 years between
the first publication on rats to the first large test-retest
study of one of the numerous techniques [20].
Thus, in 2009, a core group of researchers and clinicians
gathered together at a first meeting in London, and decided
to establish the ASL Network (http://www.asl-network.org).
This group has since met on regular occasions primarily at
meetings of the International Society for Magnetic Reson-
ance in Medicine (ISMRM) and, from 2011 to 2015, it was
supported by a European Commission-funded COST
Action to try and establish the use of ASL in dementia [18].
One of the main achievements of this action has been
the publication, together with the Perfusion Study Group
of the ISMRM, of a position paper on the current state
of ASL, the so-called ‘ASL White Paper’, indicating
clearly what sequence was thought to be providing the
best signal-to-noise ratio and what quantification
method needed to be employed [21]. Remarkably, this
paper, in addition to its 14 coauthors, was also officially
endorsed by over 230 people, representing a large pro-
portion of basic scientists and clinicians active at that
time. In addition to this landmark paper, numerous
other studies tackled the problem of reproducibility and
difference in perfusion maps obtained by the different
manufacturers (e.g. [22]). This led all major manufac-
turers to slowly change their implementation to the pre-
ferred version from the ASL White Paper.
It is, therefore, the right time now to engage with the
process of establishing a QIBA profile, and it is great
news that members of the EIBALL Committee have
agreed to bring it forward. Within its tasks, the commit-
tee will need to implement further longitudinal studies
and to refine claims to establish exactly how quantitative
assessment of cerebral perfusion can shape the future of
neurological and neuroradiological research and applica-
tions. The future now seems bright, with the potential
use of quantitative perfusion in stroke, dementia, and
brain tumours, as well as in neuroinflammation and
other neurological conditions!Within this context, it seems that many of the upcom-
ing activities linked in particular to quantitative imaging
biomarker development and validation, such as the case
in ASL, as well as its implementation within clinical
practice, fall exactly within the target publication of this
very journal, European Radiology Experimental.
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